论文信息 - Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults - 字舞流文

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

N. Heyne | Y. Miyakawa | G. Ariceta | H. Haller | G. La Manna | Sung-Soo Yoon | M. Fischereder | Jin Seok Kim | D. Kavanagh | T. Kasimatis | J. Campistol | Chiu-Ching Huang | E. Rondeau | S. Griffin | P. Chowdhury | F. Provôt | S. Cataland | G. Arepally | M. Okumi | V. Dobronravov | Y. Luque | E. Wong | J. Menne | C. Garrouste | M. Le Quintrec | D. Oh | S. Boyer-Suavet | F. Brown | B. Seitz-Polski | S. Nagaraj | G. Favre | Y. Delmas | N. Broeders | K. Garlo | J. Morelle | T. Barbour | U. Schönermarck | L. Caroti | L. Cirami | P. Campbell | I-Ru Chen | M. Scully | Manuel Praga Terente | S. Babu | G. Greenwood | M. Vinogradova | Susan Huang | T. Kirsanova | Guillaume Jeantet | É. Goffin | Sunil Nilufer Nicole Fiona Philip Josep M. Paramit Theo Babu Broeders Lietar Brown Campbell Campist | N. Lietar | Guilia Antognoli | Anja Gaeckler | Iino Fumie | Anja Muhlfeld | N. Terrada | I. Chen | Sonia Boyer-Suavet

[1] L. Greenbaum,et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab , 2020, Pediatric Nephrology.

[2] J. Menne. Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)? , 2020, Kidney international.

[3] N. Heyne,et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. , 2020, Kidney international.

[4] I. Tomazos,et al. PRO5 COMPARING PRODUCTIVITY LOSSES FROM TREATING ATYPICAL HEMOLYTIC UREMIC SYNDROME PATIENTS IN THE UNITED STATES WITH ECULIZUMAB OR RAVULIZUMAB IN AN INFUSION CLINIC OR AT HOME , 2019, Value in Health.

[5] N. Sheerin,et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study , 2019, BMC Nephrology.

[6] G. Ardissino,et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. , 2018, Kidney international.

[7] Zhao-Xue Yu,et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action , 2018, PloS one.

[8] V. Frémeaux-Bacchi,et al. Haemolytic uraemic syndrome , 2017, The Lancet.

[9] P. Ruggenenti,et al. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10] G. Ardissino,et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. , 2016, Kidney international.

[11] R. Brodsky. Complement in hemolytic anemia. , 2015, Blood.

[12] R. Torra,et al. Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento: Documento de consenso , 2015 .

[13] G. Remuzzi,et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies , 2015, Kidney international.

[14] D. Kavanagh,et al. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. , 2015, Translational research : the journal of laboratory and clinical medicine.

[15] G. Remuzzi,et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.

[16] L. Rostaing,et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[17] P. Comoli,et al. Conceiving a hematopoietic stem cell donor: twenty-five years after our decision to save a child , 2012, Haematologica.

[18] G. Remuzzi,et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[19] Giuseppe Remuzzi,et al. Atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.

[20] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[21] S. Rodríguez de Córdoba,et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. , 2015, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.